Drug affordability is rightly a top concern for Americans. President Trump recently launched an unprecedented effort to fix this problem with a proposal to tackle excessively high drug prices while still preserving incentives for medical innovation, which ensures better future health.
First, the president’s plan would cut domestic drug prices by dismantling the burdensome government approval and reimbursement policies that inhibit healthy competition. Second, the plan would combat foreign government policies that devalue intellectual property rights and create unfair pricing systems that force drug manufacturers to sell to foreign buyers at unreasonably low prices.
